

ASX/Media Release

4 March 2019

Opinion leaders present Botanix data at American Academy of Dermatology

Key highlights

- Dermatology key opinion leaders independently presented information about the Botanix development programs at the American Academy of Dermatology annual meeting recently
- Botanix also held meetings with a range of potential partners, presenting updates on the Phase 2 acne and atopic dermatitis clinical studies and the Phase 1b psoriasis program
- There were multiple education sessions examining the merits of cannabinoids in dermatology, which indicates the growing interest in the area
- Recent Botanix data on comparative performance of BTX 1503 versus OTC CBD products cited as a sign of growing support for cannabinoids from pharmaceutical companies and investors

Washington DC, 4th March 2019: Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) is pleased to announce that Botanix’s cannabidiol clinical data and product programs have been presented independently by dermatology key opinion leaders at the annual American Academy of Dermatology (AAD) meeting held over the weekend in Washington DC.

Matt Callahan, Founder and Executive Director of Botanix said: “We are very excited that key opinion leaders in dermatology are increasingly excited by the data and potential of our clinical programs in acne, atopic dermatitis and psoriasis. At a time when patients and physicians are keenly interested in discovering new therapies in cannabinoids, our clinical pipeline is the most advanced in the world and is drawing new attention from industry and potential partners.”

AAD is the largest, most influential and representative dermatology group in the United States, with a membership of more than 20,000 dermatologists and many more in attendance at its annual conference. Seminars, data presentations and educational sessions are held throughout the conference which also provides an opportunity for networking between leading dermatology companies and key opinion leaders for one-on-one discussions. AAD 2019 featured a number of presentations in relation to cannabinoids and the growing interest in exploring the potential of these new drugs to treat a range of skin diseases.

Botanix’s rising profile in the dermatology community was highlighted in presentations by some of the world’s leading key opinion leaders, featuring data and development updates from the Company’s clinical programs. Dr Leon Kircik (Associate Clinical Professor Icahn School of Medicine at Mount Sinai Medical Center) and Dr James Del Rosso (Adjunct Clinical Professor of Dermatology at Touro University) presented Botanix data at the acne boot camp, while Dr Larry Eichenfield (Chief of paediatric and adolescent dermatology at Rady Children’s Hospital-San Diego, as well as vice chairman

For personal use only

of the Department of Dermatology and a professor of dermatology and paediatrics at UC San Diego School of Medicine) presented in relation to Botanix's atopic dermatitis program. Dr Linda Stein Gold (Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, Michigan, as well as Division Head of Dermatology at Henry Ford Health System) also presented in relation to Botanix's atopic dermatitis program.

In addition to presentations from thought leaders about Botanix programs, the Company also met with multiple industry partners to present an update on the progress of Botanix's late stage clinical programs, BTX 1503 for acne and BTX 1204 for atopic dermatitis, as well the ongoing patient study for BTX 1308 for psoriasis. These meetings highlighted the interest of pharmaceutical companies and investors in the comparative data recently released by Botanix which demonstrated the superior drug delivery that the Company's Permetrex™ technology enables.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company's focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis.

Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12 week timeframe.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical study in June 2018 with completion of enrolment expected in mid-2019. The BTX 1204 atopic dermatitis Phase 2 patient study is also underway with enrolment expected to be completed in 3Q CY2019. Finally, Phase 1b BTX 1308 psoriasis patient study is in late stage enrolment and will be complete by the end of 1Q CY2019 with data available in 2Q CY2019.

To learn more please visit: <https://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Matt Callahan
Botanix Pharmaceuticals
Founder & Executive Director
+1 215 767 4184
mcallahan@botanixpharma.com

Investor enquiries

Joel Seah
Vesparum Capital
P: +61 3 8582 4800
botanixpharma@vesparum.com

Media enquiries

Haley Chartres
Hales² Consultancy
P: +61 423 139 163
haley@h-squared.com.au

For personal use only